SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vivus: into single digits
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: AlienTech who wrote (971)9/5/1998 3:40:00 PM
From: VLAD   of 1016
 
Alien,

I was told that the focus of Vivus is to be an R&D and production company from now on.

Vivus is a good example of what happens when a small company with limited resource tries to do it all for themselves.

I believe that much of the management is no longer needed now that they do not plan on doing any marketing or sales.

IMO Vivus now only needs to continue funding its research and the only thing that is left to "screw up" is production but it appears that they have finally got that part down fairly good.

Vivus IMO is not MUSE. MUSE will be replaced by Alibra which has many advantages including one dose, no refrigeration, better efficacy and less side effects. Gene Therapy IMO has some real potential in the future.

IMO the current price reflects a lack of investor confidence and poor perception of the company. I think that Vivus can end up being a good turn around story but it wont start until they report positive Q3 earnings and announce a domestic partnership. I do not think the company will be sold.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News